Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Naurex, Inc, an affiliate of Allergan plc
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03855865CT.gov Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD) | — | Withdrawn | — | — | — |
NCT03675776CT.gov Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD) | — | Terminated | — | — | — |
NCT03668600CT.gov Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) | — | Terminated | — | — | — |
NCT03614156CT.gov Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD) | — | Terminated | — | — | — |
NCT03560518CT.gov Study of Rapastinel as Monotherapy in Patients With MDD | — | Terminated | — | — | — |
NCT03352453CT.gov A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder | — | Terminated | — | — | — |
NCT03002077CT.gov Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder | — | Completed | — | — | — |
NCT02951988CT.gov A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder | — | Completed | — | — | — |
NCT02943577CT.gov A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03) | — | Completed | — | — | — |
NCT02943564CT.gov A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02) | — | Completed | — | — | — |
Show 4 more trialsShow fewer
NCT02932943CT.gov A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01) | — | Completed | — | — | — |
NCT02192099CT.gov Open Label Extension for GLYX13-C-202, NCT01684163 | — | Terminated | — | — | — |
NCT01684163CT.gov Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants | — | Completed | — | — | — |
NCT01234558CT.gov Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Major Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rapastinelum (this asset) | Naurex, Inc, an affiliate of Allergan plc | P3 | B · 59 |
| Selegiline | Corium Innovations, Inc. | P4 | BBB |
| Risperidone | Johns Hopkins University | P4 | BBB |
| Edivoxetine | Eli Lilly and Company | P3 | BBB |
| (1S,2R)-MILNACIPRAN | Allergan | P4 | BBB |
| Vortioxetine | Mayo Clinic | P4 | BBB |
| Brexpiprazole | Nova Scotia Health Authority | P4 | BBB |
| Amitriptyline | e-Therapeutics PLC | P4 | BBB |
| Duloxetine | Alar Pharmaceuticals Inc. | P4 | BBB |
+42 more in the Major Depressive Disorder cohort
Other indications for Rapastinelum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Psychiatric Disorder | — | P2 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rapastinelum in Major Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rapastinelum-major-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →